ClinicalTrials.gg
TerminatedNCT01822756Updated Feb 12, 2018Results posted

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ruxolitinib and gemcitabine in Solid Tumors and Pancreatic Cancer, sponsored by Incyte Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-12.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Dose escalation ended after Cohort B1, RUX 10 mg BID - GCSF in October 2014.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 370 studies testing gemcitabine in Pancreatic Neoplasms — 30 open to participants now, 45 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Enrollment
152nd of 353
42 · median 37
Started
2013
with 18 others
Phase 1
87 of 370
1 open now
Registered
228th of 370
by date

Among the 370 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 152nd largest by enrollment of the 353 interventional ones that give a count, is one of 19 that started in 2013, is one of 87 in phase 1, and was the 228th registered.

Pancreatic Neoplasms

3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

30 of the 370 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This is a study of ruxolitinib in combination with gemcitabine with or without nab-paclitaxel administered to patients with advanced or metastatic pancreatic cancer. The study will be conducted in two parts.

Part 1 of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of ruxolitinib when given as described to patients with advanced or metastatic pancreatic cancer. A goal of Part 1 will be to identify the maximally tolerated dose (MTD) of ruxolitinib when given with gemcitabine with or without nab-paclitaxel. This dose will be selected for use in Part 2 of the study.

Part 2 of the study will further evaluate the safety, tolerability, PK and preliminary clinical activity of ruxolitinib at the dose defined in Part 1 used in combination with gemcitabine with or without nab-paclitaxel in subjects with advanced or metastatic pancreatic cancer.

After multiple challenges of trial conduct, by mutual agreement between investigators and sponsor, dose escalation ended after Cohort B1, RUX 10 mg twice daily (BID) - GCSF in October 2014. Therefore, the MTD was not reached. No safety issues led to the decision to stop further enrollment.

Because of the early study termination, samples for pharmacokinetics and pharmacodynamics, and computed tomography for tumor burden were collected, but not analyzed; analysis data are not available. The data cutoff for this posting is 22 SEP 2015. As of the data cutoff, 1 subject was receiving treatment in the study and had been enrolled for 47 weeks. This subject had their end of treatment visit in AUG 2016. A comparison of this subjects' safety data after the cutoff date showed no clinically meaningful differences (eg, adverse events) compared with safety results that are summarized here.

03

Conditions studied

  • Solid Tumors
  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years or older
  • or cytologically confirmed adenocarcinoma of the pancreas
  • (ECOG) performance status ≤ 1
  • Requirements for prior therapy as outlined below:

    • Enrollment into Regimen A: received no more than 1 prior chemotherapy regimen for advanced or disease (not including and/or adjuvant therapy)
    • Enrollment into Regimen B: received no prior chemotherapy for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy)
  • Adequate renal, hepatic, and bone marrow function without blood product or hematopoietic growth factor support:
  • Able to swallow and retain oral medication

Exclusion criteria

Exclusion Criteria:

  • Any known to the use of gemcitabine (for enrollment in Regimen A or B) or nab-paclitaxel (for enrollment into Regimen B).
  • Evidence of uncontrolled or history of uncontrolled seizures.
  • Ongoing radiation therapy and/or radiation therapy administered within 28 days of enrollment. Subjects who have received radiation to the spine, pelvis, ribs, or femur should be discussed with the sponsor, as extensive radiation to marrow forming region may compromise a subject's ability to tolerate myelosuppressive chemotherapy. Subjects who have ongoing radiotherapy-related toxicities are not eligible.
  • Subjects who participated in any other study in which receipt of an study drug occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose.
  • Current or previous other within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or other noninvasive malignancy without sponsor approval.
  • Inability to swallow food or any condition of the upper GI tract that precludes administration of oral medications.
  • Recent (≤ 3 months) history of partial or complete bowel obstruction.
  • Unwilling to be transfused with blood components.
  • Known history of or C infection or infection.
  • Presence of ≥ Grade 2 neuropathy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Regimen A -ruxolitinib, gemcitabine

    Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).

    Drug: ruxolitinib · Drug: gemcitabine

  • Experimental
    Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim

    Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored. nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Drug: ruxolitinib · Drug: gemcitabine · Drug: nab-paclitaxel · Drug: filgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)

    Toxicities occurring during the first treatment cycle (Cycle 1) defined tolerability. Within each cohort, subjects were considered evaluable if they had received at least 40 of 56 planned doses of RUX during the 28-day surveillance period and received 2 of the 3 planned doses of chemotherapy (gemcitabine and/or gemcitabine and nab-paclitaxel) at the assigned dose level, or they had experienced a DLT.

    Time frame: Approximately 28 days

Secondary outcomes

  1. Plasma Concentrations Will be Used to Estimate Peak Plasma Concentration (Cmax) and Area Under the Plasma Concentration Curve (AUC).

    Time frame: Day 1 and Day 8

  2. Plasma Concentration of Tumor Specific Biomarkers and Cytokines Before and During Treatment.

    Time frame: Up to 6 months

  3. Clinical Activity as Measured by the Greatest Decrease in Tumor Burden Compared to Baseline.

    Time frame: Approximately 6 months

  4. Percentage of Participants With a Best Response by RECIST Criteria

    Best response was determined on the subject level using the highest overall response achieved post-baseline. In the case of stable disease (SD), measurements had to meet the SD criterion at least once after study entry at a minimum interval of 49 days. Subjects who failed to meet this criterion had best response of progressive disease (PD) if the next available RECIST evaluation after the initial scan indicated PD or not evaluable (NE) if no additional RECIST evaluations were available. Complete Response (CR) and Partial Response (PR) defined by the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. CR: Disappearance of all target and nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, or persistence of 1 or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal limits.

    Time frame: every 2 cycles starting at Cycle 3 Day 1 up to approximately 4 to 6 months

  5. Percentage of Responders

    Duration of response was measured as the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response.

    Time frame: Randomization to clinical cutoff 22Sept2015 (approx 244 days)

  6. Duration of Response

    Duration of response was the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response. Confidence intervals for median duration of response were calculated using the method of Brookmeyer and Crowley (1982).

    Time frame: Randomization to clinical cutoff 22Sept2015 (approx 244 days)

07

Results

Posted Apr 13, 2017
Limitations and caveats
In October 2014, further enrollment of additional study cohorts was stopped; Part 2 of the study wasn't conducted. Pharmacokinetic and Pharmacodynamics analyses weren't performed due to early termination. Maximum tolerated dose (MTD) was not reached.

Participant flow

Participant flow — Overall Study
MilestoneCohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1
Started1641048
Discontinued from the study1641047
Completed00001
Not completed1641047
Withdrew: Adverse event00020
Withdrew: Disease progression111726
Withdrew: Death22100
Withdrew: Lost to follow-up10101
Withdrew: Physician decision01000
Withdrew: Disease progression & patient preference20100

Outcome measures

PrimaryPercentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)

Toxicities occurring during the first treatment cycle (Cycle 1) defined tolerability. Within each cohort, subjects were considered evaluable if they had received at least 40 of 56 planned doses of RUX during the 28-day surveillance period and received 2 of the 3 planned doses of chemotherapy (gemcitabine and/or gemcitabine and nab-paclitaxel) at the assigned dose level, or they had experienced a DLT.

Time frame:
Approximately 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)
percentage of participantsCohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1
Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)0.00.020.050.00.0
SecondaryPlasma Concentrations Will be Used to Estimate Peak Plasma Concentration (Cmax) and Area Under the Plasma Concentration Curve (AUC).
Time frame:
Day 1 and Day 8

No measurements were reported for this outcome.

SecondaryPlasma Concentration of Tumor Specific Biomarkers and Cytokines Before and During Treatment.
Time frame:
Up to 6 months

No measurements were reported for this outcome.

SecondaryClinical Activity as Measured by the Greatest Decrease in Tumor Burden Compared to Baseline.
Time frame:
Approximately 6 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants With a Best Response by RECIST Criteria

Best response was determined on the subject level using the highest overall response achieved post-baseline. In the case of stable disease (SD), measurements had to meet the SD criterion at least once after study entry at a minimum interval of 49 days. Subjects who failed to meet this criterion had best response of progressive disease (PD) if the next available RECIST evaluation after the initial scan indicated PD or not evaluable (NE) if no additional RECIST evaluations were available. Complete Response (CR) and Partial Response (PR) defined by the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. CR: Disappearance of all target and nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, or persistence of 1 or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame:
every 2 cycles starting at Cycle 3 Day 1 up to approximately 4 to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response by RECIST Criteria
percentage of participantsCohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1
Overall response12.525.050.025.037.5
Complete response0.00.00.025.00.0
Partial response12.525.050.00.037.5
Stable disease25.075.020.050.025.0
Progressive disease37.50.010.00.037.5
Not evaluable6.30.00.00.00.0
Missing18.80.020.025.00.0
SecondaryPercentage of Responders

Duration of response was measured as the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response.

Time frame:
Randomization to clinical cutoff 22Sept2015 (approx 244 days)
Reported as:
Number · Percentage of responders
Percentage of Responders
Percentage of respondersCohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1
Percentage of Responders12.525.050.025.037.5
SecondaryDuration of Response

Duration of response was the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response. Confidence intervals for median duration of response were calculated using the method of Brookmeyer and Crowley (1982).

Time frame:
Randomization to clinical cutoff 22Sept2015 (approx 244 days)
Reported as:
Median · days
Duration of Response
daysCohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1
Duration of Response132.0 (NA to NA)33.0 (NA to NA)113.0 (57.0 to 533.0)244.0 (NA to NA)225.0 (57.0 to 225.0)

Adverse events

Collected over From randomization to 30 days after last visit up to approximately 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A0—10/16 (62.5%)16/16 (100%)
Cohort B (-1)—4/4 (100%)4/4 (100%)
Cohort B0 (+GCSF)—3/10 (30%)10/10 (100%)
Cohort B0 (-GCSF)—0/4 (0%)4/4 (100%)
Cohort B1—2/8 (25%)8/8 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventCohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1
AnemiaBlood and lymphatic system disorders0/161/40/100/41/8
Abdominal painGastrointestinal disorders4/160/40/100/40/8
Duodenal ulcer hemorrhageGastrointestinal disorders0/161/40/100/40/8
AstheniaGeneral disorders0/161/40/100/41/8
Pharyngeal abscessInfections and infestations0/161/40/100/40/8
Urinary tract infectionInfections and infestations0/161/40/100/40/8
DehydrationMetabolism and nutrition disorders1/161/40/100/41/8
DiarrheaGastrointestinal disorders0/160/40/100/41/8
Eye infection toxoplasmalInfections and infestations0/160/40/100/41/8
SepsisInfections and infestations2/160/40/100/40/8
Most frequent other events
Showing 10 of 196
Most frequent other events
EventCohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1
AnaemiaBlood and lymphatic system disorders9/162/46/104/43/8
ThrombocytopeniaBlood and lymphatic system disorders4/161/46/104/41/8
FatigueGeneral disorders10/164/48/102/45/8
NauseaGastrointestinal disorders4/163/48/102/43/8
NeutropeniaBlood and lymphatic system disorders3/162/42/103/40/8
DiarrhoeaGastrointestinal disorders2/163/45/101/42/8
Oedema peripheralGeneral disorders4/163/45/102/44/8
DyspnoeaRespiratory, thoracic and mediastinal disorders5/160/42/103/43/8
Pain in extremityMusculoskeletal and connective tissue disorders0/162/42/103/41/8
AlopeciaSkin and subcutaneous tissue disorders0/163/47/101/44/8

Baseline characteristics

Intent-to-Treat Subjects (ITT): All subjects who received at least 1 dose of Ruxolitinib (RUX).

Age, Continuous
Age, Continuous(years)Cohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1Total
Mean62.6 ± 8.5661.3 ± 6.4061.2 ± 9.3370.0 ± 7.6262.4 ± 8.4862.8 ± 8.45
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1Total
Female8460220
Male8044622
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(participants)Cohort A0Cohort B (-1)Cohort B0 (+GCSF)Cohort B0 (-GCSF)Cohort B1Total
06283524
110221318
2000000
08

Study locations

5 sites
  • Birmingham, Alabama, United States
  • Gainesville, Florida, United States
  • Sarasota, Florida, United States
  • Durham, North Carolina, United States
  • Nashville, Tennessee, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Sep 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2013
First posted
Apr 2, 2013
Start
Apr 2013
Primary completionActual
Sep 2015
CompletionActual
Aug 2016
Results first posted
Apr 13, 2017
Last update
Feb 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01822756
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 2, 2013
Start date
Apr 2013
Primary completion
Sep 2015
Completion
Aug 2016
Results posted
Apr 13, 2017
Last update
Feb 12, 2018

Study contacts

Fitzroy Dawkins, M.D.
study director · Incyte Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ruxolitinib · Gemcitabine

Start the discussion